John V. W. Reynders

Sun Microsystems, Inc. provides network computing infrastructure solutions. It offers its solutions under the Java technology platform, Solaris Operating System, MySQL database management system, Sun StorageTek storage solutions, and UltraSPARC processor brands. The company also develops networking computing products and technologies which include servers, storage, open source software, tools, and training. The company provides solutions to the social networking, entertainment, financial services, manufacturing, healthcare, retail, news, energy, and engineering companies. The company was founded in 1982 and is headquartered in Santa Clara, CA.

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD

Los Alamos National Laboratory operates as a multidisciplinary institution. It offers services in science, engineering, earth science, chemistry, mathematics, physics, and space science. The company was founded in 1943 and is headquartered in Los Alamos, NM.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.